What's Happening?
The FDA has reversed its previous rejections of Atara Biotherapeutics and Pierre Fabre Pharmaceuticals' cell therapy, Ebvallo, following the departure of Vinay Prasad, the former Director of the Center for Biologics Evaluation and Research. The agency
now agrees that a single-arm study with an appropriate historical control can support the therapy's approval for children with post-transplant lymphoproliferative disease (PTLD) who are positive for the Epstein-Barr virus. This decision comes after a positive Type A meeting with the FDA, where Atara and Pierre Fabre plan to submit an updated dataset from the Phase 3 ALLELE study. The FDA had previously rejected Ebvallo twice, citing issues with the trial design and manufacturing compliance.
Why It's Important?
This reversal by the FDA is significant as it highlights the potential impact of leadership changes within regulatory bodies on drug approval processes. The decision to reconsider Ebvallo's application could pave the way for its approval, providing a new treatment option for children with PTLD. This development underscores the importance of regulatory flexibility and collaboration between pharmaceutical companies and the FDA. It also reflects the agency's willingness to adapt its evaluation criteria, which could influence future drug approval strategies and timelines. The outcome of this case may encourage other companies to pursue similar pathways for their therapies.
What's Next?
Atara and Pierre Fabre are expected to resubmit their application for Ebvallo, incorporating additional patient data and extended follow-up from the ALLELE study. The companies anticipate providing a regulatory update in the third quarter. The FDA's decision on this resubmission will be closely watched by the pharmaceutical industry, as it could set a precedent for the approval of other cell therapies. The outcome may also impact the strategic planning of companies developing similar treatments, as they navigate the regulatory landscape and seek to bring innovative therapies to market.
